Limited use of genetic counselors and high rate of double mastectomy in women at average risk with early-stage breast cancer illustrate that understanding of genetic testing results is limited.
Genetic testing for BRCA gene mutation is increasingly undertaken by women unaffected by breast and/or ovarian cancers.
More women tested for the BRCA genes but no corresponding increase in mastectomy rates
Research presented at 2016 SABCS showed whether RANKL inhibition could reduce the risk for developing breast cancer in BRCA1 mutation carriers.
Bi-allelic inactivation of BRCA1 and BRCA2 are frequent events in BRCA1 breast cancers and BRCA2 breast cancers, respectively, according to a study presented at SABCS 2016.
At SABCS 2016, researchers presented study findings demonstrating whether neoadjuvant treatment, PARPi-7, BRCAness, and MP1/2 predict response to veliparib plus carboplatin therapy in patients with high-risk breast cancer.
Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.
Women who carry the BRCA1 mutation are at increased risk for serous/serous-like endometrial carcinoma after risk-reducing salpingo-oophorectomy. Yet uncertainty exists over the need to perform a full hysterectomy in these women.
Although overall risk for uterine cancer after risk-reducing salpingo-oophorectomy is not increased, the risk of serous/serous-like endometrial carcinoma is higher for BRCA1+ women.
Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.
